Little is known about stepwise deregulation of speci®c genes leading to lymphoid malignancy. Aberrant myc gene expression in transgenic mice is correlated with B cell lymphomagenesis. We generated a unique transgenic mouse model in which deregulated murine Em-N-myc transgene expression leads to development of indolent B cell lymphoma. Tumor cells were monoclonal, morphologically mature and surface immunoglobulin expressing B cells. Tumors arose in a disease course and exhibited a cytoarchitectural appearance reminiscent of human follicular lymphoma. Yet tumor cells were staged as preB since they failed to rearrange the immunoglobulin light chain genes. Retroviral insertion mutagenesis analyses of adult transgenic mice infected as newborns with murine leukemia virus revealed decreased disease latency, increased lymphoma incidence and a histologically more mature tumor type. Proviral insertion sites were not equivalent when accelerated Em-N-myc indolent lymphomas were compared to accelerated c-myc preB cell lymphomas. The bcl-2 gene was not disrupted in either spontaneous or provirally accelerated Em-N-myc lymphomas. These ®ndings suggest that tumor progression in N-myc-associated indolent B cell lymphoma can proceed along diverse pathways involving distinctly dierent combinations of deregulated and/or intact genes than those pathways described in highly aggressive forms of myc-related murine preB cell disease.
Introduction
The maturation and dierentiation of B lymphocytes is an ordered developmental process. A readily recruitable supply of B cells must be continually available to render the host capable of vigorous and highly speci®c immune responses to antigenic stimuli (Osmond, 1990; Rolink and Melchers, 1993; Kincade and Gimble, 1993; Kantor and Herzenberg, 1993; Rajewsky, 1996) . Any irreversible disruption in the maturation and dierentiation phases of B cell ontogeny can result in immunologic compromise or dysfunction, and may predispose B cells to accumulation of somatic mutations which may lead to fully transformed, malignant phenotypes (Potter, 1990; Sawyers et al., 1991; Magrath, 1992) . Extensive studies of c-myc and N-myc genes which encode nuclear transcription factors have con®rmed their participation in neoplastic transformation in vitro and tumorigenesis in vivo (Cole, 1986; Lee, 1989; Adams and Cory, 1991; Berns, 1991; Morgenbesser and DePinho, 1994; Collum and Alt, 1990) . Murine N-myc is widely expressed prenatally in developing brain, gut, kidney, lung and other neural cells. After birth, expression is restricted to B lymphocytes where N-myc transcripts are present only in preB cells. Upon dierentiation to the mature B cell stage, coincident with completion of immunoglobulin (Ig) gene expression, N-myc expression turns o and remains o (Reth et al., 1985; Zimmerman et al., 1986; Smith et al., 1992; Morrow et al., 1992) . The oncogenic potential of the human N-myc gene has been implicated in various tumors including neuroblastoma (Brodeur et al., 1984; Kohl et al., 1984) , Wilms' tumor (Nisen et al., 1986) , retinoblastoma (Lee et al., 1984) , small cell lung carcinoma , medullary thyroid carcinoma (Roncalli et al., 1994) , testis (Shuin et al., 1994) , brain (Hirvonen et al., 1994) , and breast (Mizukami et al., 1995) . Human N-myc gene expression has been observed to be elevated in several AML and ALL leukemias and leukemic cell lines (Hirvonen et al., 1991) while not detectable in pre-preB and preB leukemic cell lines (Wetherall and Vogler, 1992) . To date, the role of deregulated N-myc expression in lymphoid malignancies remains to be clari®ed.
Myc gene deregulation alone is not sucient to cause a fully transformed phenotype and requires the cooperative interactions of other gene(s) to induce a state of malignancy (Cleveland et al., 1986; Sinn et al., 1987; Cory and Adams, 1988; Harris et al., 1988; Kurie et al., 1990; Berns, 1991; Breuer et al., 1991; Takao et al., 1991) . The ability of myc genes to participate in lymphomagenesis has been reported in transgenic mice that carry a deregulated c-myc gene (Adams et al., 1985; Leder et al., 1986; Suda et al., 1987; Schmidt et al., 1988; Alexander et al., 1989; Berns et al., 1989) . In doubly transgenic mice the enhanced cancer-promoting capabilities of c-myc was demonstrated in cooperation with other deregulated genes such as bcl-2 and pim-1, contributing to a more aggressive disease course with earlier onset (Langdon et al., 1989; van Lohuizen et al., 1989; Strasser et al., 1990; Moroy et al., 1991; .
The biologic consequences of inappropriate N-myc gene expression have also been reported in transgenic mice. Following stable germline transmission of various constructs containing a murine N-myc gene, B cell tumors developed in progeny mouse lines. Some of these transgenes contained an Ig heavy chain (HC) gene enhancer and were regulated either by promoter elements of the endogenous N-myc gene or by exogenous SV40 promoter sequences. In studies of progeny lines derived from two founder mice reported by Rosenbaum et al. (1989) , a murine Em-N-myc transgene, present at 2 ± 5 copies per genome, driven by a strong exogenous promoter and missing nearly all of the 3' untranslated region gave rise to markedly elevated levels of transgenic N-myc mRNA concomitant with downregulation of endogenous N-myc expression and the appearance of highly malignant, widely-disseminated lymphosarcomas. Each progeny line revealed its individual tumor cell type including preB, preB/B and mature B cell, and showed variations in tumor cell type from generation to generation. In studies reported by Dildrop et al. (1989) two progeny mouse lines that bore an N-myc transgene (EN) regulated by endogenous promoter elements and present at 10 copies per genome developed aggressive preB and B cell lymphoblastoid tumors. Another progeny mouse line which was established with an SV40 promoter-regulated N-myc (ESN) present at ®ve copies per genome caused high-grade lymphoblastoid tumors following delayed onset. An N-myc transgene regulated by murine Ig enhancer and promoter sequences (EVN) gave rise to four tumor-bearing progeny lines with copy numbers that ranged from 10 ± 20. Stable cell cultures derived from each group of these tumors expressed N-myc mRNA at levels up to 50 times higher than that seen for expression of a single copy gene. Together, while there was apparent heterogeneity in tumor cell types among the progeny lines examined in the studies cited above, it is likely that overexpression of the N-myc transgene during very early stages of B cell dierentiation contributed signi®cantly to perturbed lineage development and disease onset.
We sought to pursue more extended analyses of deregulated N-myc expression in vivo and focused our studies on the development of transgenic mice in which transgene expression was near or at basal level. We reasoned that this would support studies of the biologic and genetic eects of mild perturbation of B cell dierentiation within a framework in which the stepwise secondary and tertiary events that contribute to lymphomagenesis could be examined. We generated an experimental fusion construct,`Em-N-myc', that contained nearly all the the murine N-myc gene under the control of the endogenous N-myc promoter sequences. The murine Ig HC enhancer element was included to confer tissue-speci®c targeting to the B cell lineage. Most of the 3' untranslated region of N-myc gene was also retained. The absence of strong, exogenous promoter elements contributed to providing a minimally deregulated genetic con®guration. In the following studies we report the development of three, independently generated lines of transgenic mice obtained by pronuclear injection of fertilized mouse embryos with low concentrations of the Em-N-myc DNA. We observed transgene expression at a basal level in the founders and in all progeny mice. At middle age, these mice exhibited a marked predisposition to the development of an indolent B cell lymphoma reminiscent of human follicular lymphoma. The novelty of this Em-N-myc disease model is that tumors arise in the context of an indolent, low-grade disease course which exhibit a mature morphologic appearance by histologic criteria even though they consist of preB cells. We also describe the acceleration of Em-N-myc lymphomagenesis by retroviral insertion mutagenesis and report the analyses of genetic loci disrupted in mice uniquely prone to indolent B cell disease. The proviral insertion sites reported earlier in the other myc-transgenic models were not found to be equivalent to those in our MoMLV accelerated Em-Nmyc tumors. Thus, we have demonstrated that low level misexpression of a minimally deregulated Em-Nmyc transgene can induce a unique form of indolent B cell lymphoma. Our studies suggest that novel insertion site loci may be associated with disease acceleration in Em-N-myc mice we rendered genetically susceptible to indolent B cell lymphoma. These data also indicate that the transition of indolent Em-N-myc lymphoma from its low-grade form to a high-grade, rapidly lethal form involves distinct and dierent pathways from those implicated in myc-transgenic mice prone to aggressive, highly malignant preB cell disease.
Results

Transgenic mice express elevated levels of N-myc transcripts in lymphoid tissues
Our studies of the N-myc gene were based on the construction of a transgene in which the mouse Ig m heavy chain (HC) gene enhancer element was coupled to the nearly full-length murine N-myc gene. A diagram of the endogenous and the engineered Nmyc genes is shown in Figure 1a . The introduction of the fusion gene into fertilized mouse embryos at concentrations ranging from 0.1 ± 0.3 mg/ml oered the potential for tissue-speci®c gene misexpression at low or basal levels with genomic disruption similar to either a translocation event or gene ampli®cation. Stable germline transmission of the Em-N-myc transgene was obtained in progeny lines (28, 30 and 32) derived from three independently generated founder mice. EcoRI restricts the endogenous N-myc gene in its entirety by cutting at the beginning and the end of the gene. As shown in Figure 1b , Southern analyses of EcoRI restricted genomic DNA obtained from mouse tail segments revealed the full-length endogenous Nmyc gene (*7.3 Kb). The higher molecular weight species represent the Em-N-myc transgene in each progeny line. Densitometric analyses determined that the transgene copy numbers were 1 in line 28, 3 ± 4 in line 30 and 2 in line 32 in mice heterozygous for the transgene. Elevated levels of N-myc expression were observed in the bone marrow, spleen and lymph nodes of asymptomatic mice and in mice with end-stage disease. Representative Northern blot hybridization analyses of total RNAs isolated from lymphoid tissues of a diseased mouse heterozygous for the Em-N-myc transgene and its non-transgenic littermate are shown in Figure 1c . The abundance of N-myc transcripts was compared to the constitutive levels observed in the murine preB cell line, 300-19, which contains one copy of the N-myc gene (Reth et al., 1985) and was indicative of basal levels of N-myc mRNA synthesis. Transgene expression was not detected in lung, brain, kidney, liver, heart and testis tissues of apparently healthy Em-N-myc mice.
Em-N-myc mice develop indolent, low-grade B cell lymphoma Mice in lines 28, 30 and 32 heterozygous for the Em-Nmyc transgene did not exhibit any apparent anomalies related to embryonic or neonatal life and appeared to thrive as healthy, fertile adults. The most striking observation was that older Em-N-myc mice revealed a marked predisposition for the development of lymphomas with characteristic patterns of B cell-type nodal involvement. The natural disease course was indolent and low-grade, and these tumors are referred to in this report as spontaneous tumors. Approximately 25% of mice in each line developed signs of disease with an average age of onset between 9 and 12 months. Gross interpretations made at autopsy indicated apparent tumor involvement of lymphoid tissues which included enlargement of the spleen and lymph nodes (primarily mesenteric and periaortic). Mice with end-stage disease frequently had white, tumorous lesions within and on the surfaces of the liver and kidneys. The lymph nodes adjacent to the liver and kidneys were often enlarged. Each line has been bred to homozygosity. Preliminary data suggest that the disease latency is shorter by 1 ± 2 months and lymphoma may develop at a frequency somewhat greater than the 25% rate observed under heterozygous conditions. None of the non-transgenic littermates (4120 mice) monitored for 24 months developed lymphoid disease.
Histopathologic evaluations were performed on formalin-®xed tissues from mice with end-stage disease and age-matched non-transgenic mice. All diseased mice examined were diagnosed as having follicular lymphoma. Mice from lines 28 and 32 were diagnosed as having the`large cell' type and mice from line 30 as having the`small cell' type. Intracytoplasmic inclusions of Ig HC protein molecules (Russell bodies) were detected at the light microscopic level in many follicular B cells. The normal lymphoid cytoarchitecture and B cell developmental transitions within germinal follicles of the spleen and lymph nodes (Inghirami and Knowles, 1992; MacClennan, 1994) were observed in lymphoid tissues obtained from In lanes 2 ± 4, arrows designate the higher molecular weight restriction fragments which indicate the presence of the transgene. Transgene copy numbers were determined by densitometric analyses of autoradiographic data by phosphorimaging techniques. (c) Northern blot hybridization analyses of lymphoid tissues from a control, non-transgenic mouse and a transgenic mouse with end-stage disease. Total RNAs were obtained from mice in line 28, were subjected to 1.25% agarose/formaldehyde gel electrophoresis, transferred to nylon membrane and hybridized with the PvuII ± PvuII fragment used in the Southern analyses. Lane 1: transgenic bone marrow, 5 mg; Lane 2: control bone marrow, 5 mg; Lane 3: transgenic spleen, 10 mg; Lane 4: control spleen, 10 mg; lane 5: transgenic lymph node, 5 mg; Lane 6: control lymph node, 5 mg healthy, non-transgenic mice. In contrast, the cytoarchitectural integrity of nodal and splenic tissues of Em-Nmyc mice with end-stage disease appeared to have been destroyed, revealing nearly complete obliteration of well-de®ned germinal follicles. The aected lymphoid tissues contained vast numbers of homogenous populations of B cells that appeared relatively mature-looking and non-lymphoblastoid. The T cells observed in these tumorous lymphoid tissues appeared normal. The histopathologic ®ndings and the natural disease course seen in the three Em-N-myc founder mice and in each of the progeny lines were consistent with a diagnosis of follicular lymphoma as described by Jae (1985) and Harris and Ferry (1992) . A representative section of spleen tissue from an Em-Nmyc mouse with end-stage lymphoma is shown in Figure 2 . Few discrete germinal follicles remain, and the splenic tissue reveals total eacement of the normal cytoarchitecture with massive accumulations of tumor cells. In the liver of this and other similarly aected Em-N-myc mice with hepatic tumor involvement, tumor cells were consistently observed surrounding blood vessels. This gave the appearance of migration of tumor cells from the blood stream to sites within the liver parenchyma.
Em-N-myc tumor cells are clonal preB lymphocytes with a histologically mature-looking appearance
Monoclonal tumor cell populations (monoclonality) are a feature of the fully malignant phenotype in many human and experimental murine B cell tumors (Rolink and Melchers, 1993; Jae, 1985; Yunis et al., 1987; Zelentz et al., 1990; Harris and Ferry, 1992; Melchers et al., 1994) . Immunophenotypic analyses have determined that patterns of clonality in human follicular lymphoma are identical in lymphoid and non-lymphoid tissues with tumor involvement in each patient. Hallmarks of normal B cell dierentiation include Ig HC gene rearrangement of one allele, with productive rearrangement precluding recombination of the other allele. Ig light chain (LC) gene rearrangement follows a similar course, and in mice over 95% of LC rearrangements occur in the kappa gene. Immunogenotypic analyses were performed on lymphoid tissue DNAs obtained from Em-N-myc mice with end-stage disease to determine the status of Ig HC and LC chain gene rearrangements and the clonal nature of the tumor cells. Southern hybridization analyses of EcoRIrestricted DNAs from lymphoid and companion liver tissues with grossly apparent tumor involvement revealed that Ig HC gene rearrangements were observed in all Em-N-myc tumors examined ( Figure  3 ). In all cases studied, we observed identical rearrangement patterns in tumorous companion lymphoid and liver tissues. These analyses con®rmed tumor cell monoclonality and suggest that each tumor probably arose from a single tumor cell. Southern blot hybridization studies revealed no rearrangements of either the kappa or lambda LC genes in any of the Em-N-myc tumors examined in each progeny line (data not shown). Absence of Ig LC rearrangements in the Em-N-myc tumor cells indicates that they are preB cells by B cell dierentiation criteria.
Immunophenotypic analyses performed by¯ow cytometry characterized each tumor cell population examined as B lymphocytes. Lymph node and spleen cells obtained from healthy, non-transgenic and heterozygous transgenic mice with end-stage disease were analysed using antibodies directed against murine surface determinants including IgM/G, glycoprotein B220, Thy-1.2 and Mac-1. Representative examples shown in Figure 4 have revealed that lymphoid cells from normal and diseased mice exhibit dierent reactivity pro®les when examined for expression of B and T cell-speci®c markers, surface IgM/G, B220 and Thy1.2. Lymph node and splenic cell populations obtained from healthy, non-transgenic littermates displayed characteristic patterns indicative of both relatively mature and mature B cells. In contrast, the B cell populations obtained from Em-N-myc mice with end-stage lymphoma consisted of far fewer fully dierentiated B cells and had a predominance of less mature B cells, indicative of an apparent shift to a less dierentiated B cell population. T cell populations were reduced in thymic tissues of mice with overt B cell disease due in part to massive in¯uxes of tumorous B cells into the thymus. An increase of 10 ± 20 fold was observed in the number of B220 expressing cells in thymic tissues of mice with end-stage lymphoma compared to non-transgenic littermates. These observations con®rmed our diagnostic histologic evaluations that tumorous B cells colonized thymic tissues in fulminant lymphoma. We also analysed B220 expression pro®les of diseased Em-N-myc spleen cells and consistently observed reactions of lesser intensity as compared to control, non-transgenic spleen cells. B220 reactivity in tumorous Em-N-myc lymph node cell populations exhibited a marked increase in the number of B220-expressing cells (Figure 4 ). Parallel studies using anti-Mac-1 antibody con®rmed that the Em-N-myc tumor cells were not derived from the macrophage lineage. For line 28, lymphoid cells from ®ve Em-N-myc mice with lymphoma and ®ve healthy, non-transgenic littermates were examined by¯ow cytometry as well as two diseased, transgenic and two healthy, non-transgenic mice each from lines 30 and 32. Together, these analyses demonstrated that the tumor cells were of the B cell lineage and were generally less dierentiated than those in nontransgenic, control mice.
The bcl-2 gene is intact in spontaneous Em-N-myc tumors
In 60 ± 90% of human follicular lymphomas the bcl-2 and Ig HC genes undergo a translocation known as t(14;18), a genetic event that accounts for overexpression of the bcl-2 gene and the delay of apoptosis or programmed cell death in B cells (Tsujimoto et al., 1984; Harris and Ferry, 1992; Levine and Hoover, 1992; Vaux et al., 1988; Nunez et al., 1990) . The appearance of prolonged cell survival and the delay of full differentiation within the B cell population in follicular lymphoma are consistent with disruption of the normal apoptotic pathway(s). However, we did not detect disruption of the bcl-2 gene in any of the spontaneous Em-N-myc mouse tumors subjected to Southern hybridization analyses using murine bcl-2 hybridization probe fragments mbcl-2 3028 (provided by Dr Stanley Korsmeyer, Washington University, St Louis, MO) and mbcl-2 5.4 and 3.3 (provided by Dr Kay Huebner, Jeerson Medical School, Philadelphia, PA).
Em-N-myc tumor cells do not develop into stable cell cultures, but are transplantable in vivo Tumor cells obtained from Em-N-myc mice with endstage lymphoma failed to develop into stable cell lines when cultured in vitro. Tumor cells were isolated from bone marrow, lymph node and spleen and were cultured either as total cell populations or as Percoll gradient-enriched lymphoid cell populations. In all instances, Em-N-myc tumor cells displayed the phenotype of marked survival advantage and could be maintained for 2 ± 8 weeks in vitro. Temporal light microscopic examinations revealed little evidence of cell division and viable cell counts con®rmed that the tumor cells were non-proliferating cell populations.
Lymph node and spleen cells from diseased transgenic mice in lines 28 and 32 were transplanted by tail vein injection into syngeneic B6D2/F1 mice of the same gender at 2 ± 3 months of age. The results of these studies which demonstrate the neoplastic properties of the Em-N-myc tumor cells from two transgenic progeny lines are shown in Retroviral insertion mutagenesis has been used successfully to induce or accelerate lymphomagenesis and to identify candidate genetic loci associated with the appearance of progressively more malignant phenotypes (Weiss et al., 1985; Berns, 1991; Gray, 1991; Kung and Vogt, 1991) . The pim-1 gene was isolated and characterized (Selton et al., 1986; Hilkens et al., 1986; Nadeau and Phillips, 1987) following the development of adult T cell lymphoma in mice infected as newborns with Moloney murine leukemia virus (MoMLV). Pim-1 transgenic mice were observed to develop spontaneous lymphoid disease infrequently. When mice transgenic for the pim-1 gene were infected with MoMLV, they revealed a remarkable propensity for proviral insertion into the c-myc and N-myc genes. This was coincident with a more rapid disease course, implying synergism between the pim-1 and myc genes in lymphoma progression Schmidt et al., 1996) . The usual mode of provirally induced deregulation involves overexpression of wild-type myc gene following preferential insertion most commonly into non-coding regions of myc Dolcetti et al., 1989; van Lohuizen et al., 1989 van Lohuizen et al., , 1991 Haupt et al., 1991) . Retroviral insertion into several other candidate loci (bmi-1, pal-1, emi-1, bla-1 and bup) has been reported following MoMLV infection to accelerate preB cell disease in c-myc transgenic mice. A novel zinc ®nger protein has been characterized as the bmi-1 gene product (Haupt et al., 1991; van Lohuizen et al., 1991) , and mice transgenic for bmi-1 can cooperate with c-myc in acceleration of lymphomagenesis (Haupt et al., 1993) . Retroviral insertion analyses of mice null mutant for pim-1 revealed the identity of a functionally compensatory gene, pim-2 (van der Lugt et al., 1995). The pal-1 locus has been further characterized and found to contain the g®-1 gene which encodes another zinc ®nger protein (Scheijen et al., 1997) . To date, the emi-1 and bla-1 loci have not been characterized.
In our experiments, non-transgenic and homozygous transgenic Em-N-myc mice (line 28) were injected intraperitoneally within 24 h of birth with 0.2 ml of 2610 5 PFU/ml Moloney murine leukemia virus. The results of these studies are shown in Figure 5 . Transgenic mice infected with MoMLV developed a markedly accelerated disease course in which mice began to succumb to B cell disease at 3 ± 4 months of age as compared to 12 months of age observed in spontaneous tumor development. The frequency of accelerated disease in the MoMLV infected transgenic population was about 72%, a dramatic increase over the spontaneous rate of 25% we had observed previously in Em-N-myc heterozygotes. Non-transgenic mice infected with MoMLV began to develop adult T cell lymphoma by 4 months of age at a frequency of 56% (13/23 mice). Mice autopsied with end-stage disease were observed to have nodal involvement typical for each disease type: non-transgenic mice revealed a typical T cell disease nodal pattern, while transgenic Em-N-myc mice with MoMLV induced disease exhibited a nodal distribution often seen in B cell lymphomas. Histologic analyses of MoMLV induced tumors revealed that the accelerated Em-Nmyc tumors were plasma cell lymphomas, a highly malignant and aggressive form of mature B cell lymphoma. Interestingly, the immunogenotypic analyses by Southern hybridization of DNAs obtained from each MoMLV-accelerated Em-N-myc tumor revealed that the kappa LC genes had not undergone rearrangement in any of the tumors examined (data not shown).
Accelerated lymphomagenesis in Em-N-myc mice does not involve disruption of the same genetic loci as those in myc transgenic mice prone to aggressive preB cell disease Synergistic actions between myc and several distinct proviral insertion site loci have been implicated in the progression of high-grade murine, transgenic preB cell lymphoma to an even more aggressive form (Haupt et al., 1991; van Lohuizen et al., 1991) . Our comparative analyses focused on the loci most frequently implicated as cooperative with myc genes in experi- Figure 5 Incidence of spontaneous and retrovirally accelerated lymphomas. Mice were inoculated with 0.2 ml of 2610 5 PFU/ml Moloney murine leukemia virus intraperitoneally within 24 h of birth. Mice were included in the experimental data when they became one month old. Mice were observed daily following inoculation, sacri®ced when moribund and tissues obtained for various analyses. All MoMLV-injected nontransgenic control mice that developed symptoms were found to have developed adult T cell lymphoma based on characteristic nodal distribution patterns observed at autopsy and histopathologic analyses. All symptomatic MoMLV-injected transgenic mice were found to have developed B cell lymphoma based on nodal patterns typical of B cell disease noted at autopsy and by histopathologic criteria. MoMLV-injected mice that survived to 10 months of age (the end-point of the study) were euthanized and found to have no evidence of lymphoma upon autopsy. No lymphomas were noted at autopsy of uninoculated, nontransgenic sib-mated C57BL/ 6xDBA/2 hybrid mice that died in the colony between the ages of 9 and 24 months (n=53) mental B cell lymphomas: the pim-1, bmi-1 and pal-1 loci. Using murine hybridization probe fragments speci®c for the pim-1 (Nadeau and Phillips, 1987) , bmi-1 (Haupt et al., 1991) and pal-1 loci (van Lohuizen et al., 1991), we screened panels of MoMLV-induced tumors from non-transgenic and transgenic Em-N-myc mice for evidence of proviral integration into these sites. By Southern blot hybrid-ization studies using diagnostic enzymes EcoRV or KpnI, we did not detect disruption of the bmi-1 or pal-1 regions in any provirally induced tumors in non-transgenic or accelerated tumors in Em-N-myc mice. As shown in Figure 6 , we observed disruption of the pim-1 gene in ®ve out of 20 (25%) accelerated Em-N-myc tumors by TaqI restriction fragment resolution and Southern blot hybridization analyses. In contrast, none of the 13 (0/ 13) MoMLV-induced tumors exam-ined from nontransgenic mice had disruption of the pim-1 gene. No proviral insertions were detected in the bmi-1 and pim-1 loci in any of the spontaneous Em-N-myc tumors screened from each of three stable progeny mouse lines (data not shown).
bcl-2 gene is not disrupted in MoMLV accelerated Em-N-myc B cell lymphoma
The synergistic association between overexpressed bcl-2 and deregulated myc genes has been implicated in lymphoid tumor progression (Strasser et al., 1990; McDonnell and Korsmeyer, 1991) . When analysed for the structural integrity of the bcl-2 gene, we observed no evidence of its disruption in MoMLV induced or accelerated tumors obtained from 13 non-transgenic and 20 Em-N-myc mice, respectively. These results suggest that global genetic perturbations involving the bcl-2 gene had not apparently contributed either to retroviral induction of adult T cell lymphoma in nontransgenic mice or in the acceleration of Em-N-myc tumor progression from an indolent to a high-grade form of B cell lymphoma following proviral integration.
Discussion
We have generated a novel transgenic mouse model for indolent B cell lymphoma. The observed murine disease is a low-grade B cell neoplasia of middle-age onset which involves lymph nodes, spleen and other non-lymphoid tissues. The molecular and cellular characterizations of the stable progeny mouse lines independently derived from three dierent founder mice are shown in Table 2 . The Em-N-myc indolent lymphoma is reminiscent of human follicular lymphoma (FL) in its natural disease course and histologic appearance. The biologic features of human FL and murine Em-N-myc disease are detailed in Table 3 . FL is one of the most common non-Hodgkin's lymphoma in humans and is generally seen in middle aged adults. Disease onset in Em-N-myc mice was consistently observed between 9 and 12 months of age, approximately middle age when the average lifespan of a laboratory mouse is about 2 years. The indolent phase of human follicular lymphoma can continue for 3 ± 15 years from initial diagnosis before transition to a more high-grade phase of the disease is seen. Similarly, Em-N-myc mice experience a long, apparently disease-free state and can live for 1 ± 2 months following initial Figure 6 Southern blot analyses of MoMLV insertion into pim-1 gene. DNAs from accelerated tumors in transgenic mice and induced tumors in non-transgenic (control) mice were restricted with TaqI, subjected to 0.8% agarose gel electrophoresis, transferred to nylon membrane, and hybridized with the pim-1a probe, a 933 bp BamHI fragment (Nadeau and Phillips, 1987) which spans intron D and includes exon sequences on either side. Lane 1: l HindIII DNA marker; Lane 2: lymph node from MoMLV/transgenic mouse #2; Lane 3: spleen from MoMLV/ transgenic mouse #11; Lane 4: tail from MoMLV/transgenic mouse #11; Lane 5: spleen from MoMLV/transgenic mouse #18; Lane 6: thymus from MoMLV/control mouse #21; Lane 7: lymph node from MoMLV/transgenic mouse #27; Lane 8: tail from MoMLV/transgenic mouse #27. Endogenous con®guration of the pim-1 gene is denoted by asterisk. Arrow indicates disruption of one allele of pim-1 gene by MoMLV insertion seen in lanes 2 and 5. The fragments representative of disrupted alleles were approximately 6 Kb in size Lymph node, spleen, bone marrow In 60 ± 90% of human FL cases, lymphomagenesis is attributed in part to elevated levels of bcl-2 protein.
However, the role of bcl-2 gene and its family members remains to be fully de®ned in normal and neoplastic lymphoid tissues (Hamilton et al., 1991; Zutter et al., 1991; Yano et al., 1992) and in persons with follicular lymphoma in which other genetic translocations have been identi®ed (Frizzera et al., 1991; Hillion et al., 1991; Ladanyi et al., 1992; Rimokh et al., 1993; Straka et al., 1993; Sole et al., 1994; Wlodarska et al., 1994) . Other variations in FL presentation include a transcriptionally silent rearranged bcl-2 gene (Wang et al., 1993) and the¯oral variant (Goates et al., 1994) . These data suggest that deregulation of bcl-2 expression may be induced by a variety of molecular events and conditions. Experimental studies in vivo have provided evidence of the biologic eects of bcl-2 protein overexpression. Bcl2/Ig transgenic mice developed benign reactive follicular hyperplasia with extended survival of B cell populations, but did not develop follicular lymphoma (McDonnell et al., 1989) . A small number of the bcl-2/ Ig mice were observed to develop immunoblastic lymphoma, a highly malignant B cell lymphoma, coincident with a c-myc gene translocation to the Ig HC locus on an endogenous allele (McDonnell and Korsmeyer, 1991) . Since unique functional relationships have been described between the bcl-2 and c-myc genes in vivo, despite our observations of an apparently intact bcl-2 gene in spontaneous Em-N-myc lymphomas, we are now studying the expression patterns of members of the bcl-2 gene family throughout the lifetime of Em-N-myc and their strain-matched nontransgenic mice.
The human FL tumor cell immunophenotype can generally be characterized by the appearance of clonal, mature B lymphocytes, by the rearrangements of both Ig HC as well as LC genes and by the expression of surface IgM/G and B220 glycoprotein. Tumor cells that overexpress bcl-2 protein display extended cell survival and are unable to proliferate in vitro. The Em-N-myc murine form of indolent lymphoma revealed a remarkably similar tumor cell phenotype which includes a relatively mature B cell by morphologic criteria, rearranged Ig HC genes, expression of surface IgM (mHC moiety) and B220 molecules, marked cell survival advantage in vivo and in vitro, and the failure of cell populations to expand in vitro. Within the context of the histopathologic evaluation of a relatively mature B cell type and the immunophenotypic assessment of sIg and B220 expression, the Em-N-myc tumor cells can be classi®ed as relatively mature. However, the unrearranged con®guration of both the kappa and lambda light chain genes de®nitively staged these tumor cells as preB cells. In the normal course of B cell development, Ig gene rearrangements and expression coincide temporally with turning o of N-myc expression. The Ig HC enhancer element in our Em-N-myc transgene successfully targeted cells of B lineage. Under conditions of deregulated, constitutive N-myc expression of the transgene, it might be expected that key steps in B cell dierentiation including Ig LC expression would be disrupted. The Em-N-myc tumor phenotype is unique since it is a non-immunoblastic preB cell population in a histologically low-grade tumor associated with a long, protracted disease course.
Our results contrast two reported studies in which N-myc transgenes under heterozygous conditions induced highly penetrant, aggressive and rapidly fatal preB/B cell disease in mice by 3 ± 6 months of age. Several factors may contribute to the dierences in disease phenotypes observed with the N-myc transgenes, namely, the use of mouse strains expressing dierent H-2 antigens, the positional eect or local environment of transgene integration, transgene copy number, strength of their promoter elements and transgene expression levels. The presence of a vigorous SV40 promoter resulted in elevated N-myc expression levels and gave rise to highly malignant lymphosarcomas on the hybrid C57BL6/SJL (H-2b/s) background (Rosenbaum et al., 1989) . The C57BL6/SJL lines were maintained by matings of transgenic males to C57BL6/ SJL females, providing an equal genetic representation of C57BL6 and SJL reminiscent of the original embryo genotype. Dildrop et al. (1989) introduced several Nmyc fusion gene constructs with either exogenous or endogenous promoter elements into C57BL6/CBA (H2b/k) mice. These tumor-bearing mouse lines were maintained by backcrossing to C57BL6 females which provided a greater contribution of the C57BL6 genotype and H-2b haplotype with each subsequent generation. Elevated transgene expression levels and the variable appearance of lymphomagenesis, each with an individual B cell phenotype, could have been due, in part, to the unique hybrid C57BL6/CBA (H-2 b/k) background of each progeny line. Our Em-N-myc progeny lines were maintained by random sib matings on the C57BL6/DBA-2 (H-2b/d) background, probably the least genetically de®ned of the backgrounds being compared because of the variability of strain contributions present in each mouse. Despite the background heterogeneity, the Em-N-myc disease phenotype of indolent lymphoma has been stably maintained in each progeny line for 410 generations. It is possible that susceptibility and/or resistance to lymphomagenesis and the nature of the disease course are a function of these strain dierences. Since the sites of transgene insertion have not been reported in any of these studies, no conclusions can be made related to the in¯uences of local chromosomal environment on transgene expression. The unifying features of the aggressive, high-grade transgenic N-myc lymphomas (Rosenbaum et al., 1989; Dildrop et al., 1989) were the high levels of transgene expression noted in tumors and tumor-derived cell lines, and the ability of the tumor cells to adapt stably to growth in vitro. In marked contrast, our Em-N-myc mice exhibited basal level transgene expression and the cells obtained from tumors failed to proliferate in vitro. Rosenbaum et al. (1989) reported that mice in two progeny lines developed aggressive lymphosarcomas (one preB cell, the other B cell) due to the expression of an Em-N-myc construct regulated by SV40 promoter sequences and missing nearly all of the 3' untranslated region of N-myc. Transgene expression was 20 times greater than single copy (*basal) gene level of N-myc expression. Since transgene copy numbers were low (2 ± 5) in these two mouse lines, the elevated levels of transgene expression may have been due, in part, to the in¯uence of a strong exogenous regulatory element. In the studies reported by Dildrop et al. (1989) three constructs were used: ESN: driven by SV40 promoter sequences, EN: similar to the Em-N-myc construct we have used including a nearly intact 3' untranslated region and the endogenous N-myc promoter elements, and EVN: murine N-myc regulated by Ig HC gene enhancer and promoter sequences. Transgene expression levels in stable cell lines derived from resultant lymphoblastoid tumors (preB, mature B, and variant of B cell types) were reported to be 50 times greater than basal level expression.
The consensus is that initial genetic perturbations that occur in a committed B cell precursor may contribute to genomic instability and defects in DNA repair mechanisms which increase the chances for subsequent mutations and developmental dysfunctions. Since endogenous murine N-myc gene expression has been shown to be temporally regulated during B cell maturation, shutting o as B cells progress from pre B cell to immature B cell to mature B cell, deregulated N-myc expression during that stage-speci®c developmental transition may predispose B cells to additional irreversible genetic events that impair normal dierentiation. In those progeny lines reported to have elevated levels of N-myc transgene expression in association with highly malignant preB cell disease, signi®cant mutations may have occurred in rapid succession or nearly simultaneously at very early stages of development, giving rise to highly penetrant, aggressive lymphoblastoid tumors.
In contrast, the window of time is quite dierent in the observed disease course of indolent Em-N-myc lymphoma. Constitutive, basal level Em-N-myc gene expression predisposes mice to indolent lymphoma at a rate of 25% in each progeny line by 9 ± 12 months of age. The fact that only 25% of heterozygous Em-N-myc mice in each of three progeny lines develop disease supports the concept that multiple hits (mutations) are required to obtain a fully transformed phenotype. In 75% of Em-N-myc mice in each line, apparently no subsequent, biologically relevant mutations or constitutive deregulation of gene function has occurred since lymphomas do not develop. The interval between the developmental time when the primary Em-N-myc mutation has been manifested (N-myc expression begins at birth in B cells) and any additional signi®cant mutations is much greater than that in the aggressive, transgenic N-myc lymphomas. That time interval and the speci®c mutations or dysfunctions that reliably ensue in 25% of Em-N-myc mice foster the progression of a distinct neoplastic disease. This oers an entirely novel genetic background on which to search for genes capable of unique synergistic actions.
Retroviral insertion mutation analyses revealed the dramatic development of a high-grade B cell lymphoma in 72% of Em-N-myc mice infected with MoMLV. Of the genetic loci most frequently implicated in retrovirally accelerated myc-related B cell disease (pim-1, bmi-1 and pal-1), we determined that the pim-1 gene was disrupted in 25% of Em-N-myc mice with accelerated lymphoma. These data indicate that pim-1 has the ability to cooperate in the acceleration of two, very distinct B cell lymphomas on dierent genetic background of susceptibility. While mutations of the murine bmi-1 and pal-1 loci have been identi®ed as the necessary, cooperative events for acceleration of transgenic c-myc preB cell disease, these loci were not apparently involved in acceleration of the Em-N-myc lymphoma. The fact that the bcl-2 gene was not disrupted in MoMLV accelerated Em-N-myc lymphomas precludes an obvious role for this gene in virusmediated lymphomagenesis.
In the remaining 75% of Em-N-myc mice in which no other common proviral sites could be identi®ed, accelerated lymphomagenesis induced by MoMLV infection must invoke the use of unique pathways and mechanisms involving disruption of dierent loci than those presently implicated in the acceleration of cmyc-associated preB cell disease. We have begun genomic library preparation and cloning studies to retrieve¯anking DNA elements from MoMLV accelerated tumor DNAs in an eort to identify proviral integration sites unique to the Em-N-myc background. We anticipate that the characterization of novel integration sites will permit analyses of genetic loci associated with the transition from an indolent, low-grade form to an accelerated, highly aggressive form of B cell lymphoma.
When evaluating the Em-N-myc mouse disease system as a possible candidate model for human FL, we must consider that numerous variant forms of human follicular lymphoma have been reported that re¯ect considerable heterogeneity in disease presentation with regard to translocations including t(14;18), t(11;14), t(2;18), t(8;14) and t(14;19), expression levels of bcl-2 protein and disruption of the c-myc gene (Frizzera et al., 1991; Hamilton et al., 1991; Hillion et al., 1991; Price et al., 1991; Zutter et al., 1991; Ladyani et al., 1992; Yano et al., 1992; Finke et al., 1993; Mitani et al., 1993; Rimokh et al., 1993; Straka et al., 1993; Wang et al., 1993; Goates et al., 1994; Marin et al., 1994; Sole et al., 1994; Wlodarska et al., 1994) . The role of bcl-2 protein in human FL is not entirely clear. Firstly, 10 ± 40% of tumors do not have a t(14;18) translocation yet may or may not overexpress bcl-2 protein. Secondly, the bcl-2 gene can be silent in lymphomas with a t(14;18) translocation. Lastly, t(14;18) translocations can be found in normal and hyperplastic lymph nodes and tonsils as well as in persons with minimal residual disease. The role of altered N-myc expression in human lymphoid cancers remains to be further de®ned since overexpression has been reported in some tumor cell types and not in others. The most notable dierence between the human and murine lymphoma cell populations appears to be that of Ig LC gene rearrangements. It must be determined how functionally mature the Em-N-myc tumor cells are based on other surface and intracellular antigenic determinant analyses corresponding to those that characterize human FL tumor cells.
In considering functional equivalencies in indolent lymphomagenesis in human and mice, the genes that participate in disease onset and progression to endstage may be dierent in structure and/or function yet may give rise to the same biologic and clinical consequences with similar histologic features. It may be that follicular lymphoma in humans has a parallel clinical disease form in Em-N-myc mice with the primary variance being the stage of tumor B cell dierentiation. The dearth of animal models with which to study the genetic progression from low-grade to high-grade disease has hindered research and development of speci®c clinical treatments for this particular human B cell neoplasia. Further examination of the novel Em-N-myc transgenic mouse model will oer the unique opportunity to study stepwise B cell lymphomagenesis from an indolent to a high-grade spontaneous form and its aggressive, provirally accelerated form. These studies should determine the advantages of this mouse model for studying the genetic and molecular mechanisms that lead to human forms of indolent B cell lymphoma.
Materials and methods
DNA construct
Transgene expression was targeted to lymphoid cells using a fusion construct Em-N-myc. A genomic murine N-myc clone was derived from mouse plasmacytoma 46B and its DNA was restricted with SacI and EcoRI to generate a fragment in which 1147 base pairs from the 5' end of the genomic N-myc gene had been deleted. The 682 bp long XbaI ± EcoRI fragment of the murine Ig HC gene enhancer element (Eu) (Gillies et al., 1983) was joined to the N-myc sequence at the SacI site. A 214 bp deletion was generated between HincII (at nt 6381) and AvaII (at nt 6595) sites to discern transgenic from endogenous N-myc transcripts. The full-length fusion construct was cloned in plasmid vector, pBS, between the XbaI and EcoRI polylinker sites. For microinjection, the Em-N-myc fusion transgene was restricted from the plasmid vector with XbaI and EcoRI, separated by low-melting point agarose gel electrophoresis in Tris-borate buer, and recovered on NA45 membrane (Schleicher & Schull, Keene, NH), and eluted in 1.0 M NaCl, 0.1 mM EDTA, 20 mM Tris, pH 8.0. Following precipitation, DNA was adjusted to concentrations of 0.1 ± 0.3 mg/ml by resuspension in 5 mM NaCl, 5 mM Tris, pH 7.4, 0.1 mM EDTA (microinjection buer), and centrifuged at 20 000 g for 30 min to remove particulate matter prior to use in pronuclear injection of fertilized mouse embryos.
Transgenic mice
Progeny lines 28, 30 and 32 were derived from three, independently-derived founder mice (#28, #30 and #32) generated by microinjection of fertilized mouse embryos at the single-cell stage. The genetic strain used for microinjection was C57BL/6xDBA/2/F1 (Jackson Labs, Bar Harbor, ME). The same fusion construct, Em-N-myc, was used for all pronuclear injections. Microinjected embryos were incubated until the two-cell stage and then surgically implanted into pseudopregnant outbred CD1 females (Charles River Laboratories, Wilmington, MA). Progeny lines were initially maintained on the hybrid background as heterozygotes by sib matings, and later successfully bred to homozygosity. Mice were observed for normal neonatal development and for signs of disease. Mice were sacri®ced when moribund at which time tissues were taken for DNA, RNA and histopathologic analyses, and lymphoid cell suspensions were prepared for¯ow cytometry, tissue culture, and tumor cell transplantation.
DNA/RNA analyses
Southern blot hybridization methods used were as described by Sheppard et al. (1991) . The diagnostic probe used to identify the presence of the transgene was the PvuII fragment (*1100 bp) of N-myc, Exon II, when used on EcoRI restricted genomic DNAs. RNA was obtained from mouse tissues according to the protocol of Chomczynski and Sacchi, (1987) . The 1049 bp ClaI ± ScaI fragment containing sequences within the third exon of N-myc was used to identify N-myc-speci®c transcripts in Northern analyses. The 300-19 murine preB cell line was provided by Dr Fred Alt, Harvard Medical School, Boston, MA, USA. 300-19 cells constitutively express a single copy of the Nmyc gene which was used as a molecular marker of basal level expression in Northern analyses. Mouse Ig HC enhancer and Ig kappa LC probe fragments were provided by Dr Timothy Manser, Thomas Jeerson Medical College, Philadelphia, PA, USA and the mouse Ig lambda LC probe fragment was provided by Dr Mel Bosma, Fox Chase Cancer Center, Philadelphia, PA, USA. Mouse bcl-2 genomic probe fragments were provided by Dr Stanley Korsmeyer, Washington University, St Louis, MO, USA and Dr Kay Huebner, Thomas Jeerson Medical College, Philadelphia, PA, USA.
Flow cytometry
Single color, log plot¯ow cytometric studies of Em-N-myc tumor and control lymphoid cell suspensions were performed using four immunoreagent pairs in indirect immuno¯uorescence analyses: Rat anti-mouse IgM followed by reaction with¯uorescein (FITC)-conjugated goat anti-rat IgG; rat anti-mouse B220 (6B2) followed by reaction with FITC-conjugated goat anti-rat IgG; rabbit anti-mouse Mac-1 followed by reaction with FITC-conjugated goat antirabbit IgG; and rat anti-mouse Thy-1.2 followed by reaction with FITC-conjugated goat anti-rat IgG. These reagents were provided by Dr Timothy Manser, Thomas Jeerson Medical College, Philadelphia, Pennsylvania and Dr Ihor Lemischka, Princeton University, Princeton, New Jersey. For each reaction, 1 ± 2610 6 cells were incubated with 0.01 mg each of the primary and secondary antibodies, and processed according to standard protocols. 5000 ± 10 000 recorded events were analysed per reaction.
Retroviral insertion mutagenesis
Newborn mice homozygous for the Em-N-myc transgene and non-transgenic strain-matched (C57BL/6xDBA/2) mice were injected intraperitoneally with 0.2 ml of 2610 5 PFU/ ml of MoMLV within 24 h of birth. Mice were sacri®ced when moribund, and tissues and cells were taken for various analyses. Moloney murine leukemia virus (CL4) was provided by Dr Stephen Go, Columbia University, New York, USA. Plasmid pMLV1a was provided by Dr Hung Fan, UC-Irvine, Irvine, California. Fragments derived from pMLV1a for use as hybridization probes included the 770 bp XbaI ± BamHI fragment of the 5' end of the MoMLV envelope gene and the 363 bp KpnI ± AatII fragment of the U5 region of the LTR. The murine pim-1a probe fragment (Nadeau and Phillips, 1987) was used to discern disruption of pim-1 following either TaqI or EcoRI restriction of genomic DNA. The murine hybridization probe fragment for recognition of the bmi-1 locus was provided by Drs Haupt and Adams, Walter and Eliza Hall Institute, Melbourne, Australia and for the pal-1 locus by Drs van Lohuizen and Berns, Netherlands Cancer Institute, Amsterdam, The Netherlands.
